Some research reports indicated that IL2 region seems to play a role in the response to rituximab in SLE patients (Marquez et al., 2013); Moreover, TLR9 plays important role in immunopathology of SLE, because increased apoptosis and/or clearance deficiencies in SLE are considered to result in increased amounts of circulating plasma DNA, which may act as TLR agonists and subsequently provide B cell activation signals (Celhar et al., 2012). The gene discussed is TLR9; the disease is systemic lupus erythematosus.